| __timestamp | Ascendis Pharma A/S | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 504755000 |
| Thursday, January 1, 2015 | 9415000 | 838526000 |
| Friday, January 1, 2016 | 11504000 | 1177697000 |
| Sunday, January 1, 2017 | 13482000 | 1320433000 |
| Monday, January 1, 2018 | 25057000 | 1556200000 |
| Tuesday, January 1, 2019 | 48473000 | 1834800000 |
| Wednesday, January 1, 2020 | 76669000 | 1346000000 |
| Friday, January 1, 2021 | 160180000 | 1824900000 |
| Saturday, January 1, 2022 | 221227000 | 2115900000 |
| Sunday, January 1, 2023 | 264410000 | 2631300000 |
| Monday, January 1, 2024 | 284545000 | 2954400000 |
Infusing magic into the data realm
In the competitive landscape of biopharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ascendis Pharma A/S have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Regeneron's SG&A expenses surged by over 420%, peaking at approximately $2.63 billion in 2023. This reflects their aggressive expansion and investment in marketing and administrative capabilities. In contrast, Ascendis Pharma, a smaller player, exhibited a more modest increase of around 410%, reaching $264 million in the same year. This growth underscores their strategic scaling efforts in a highly competitive market. The data highlights the contrasting financial strategies of these companies, offering insights into their operational priorities and market positioning. As the biopharma sector continues to evolve, these trends provide a window into the future strategies of these industry titans.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Comparing Revenue Performance: Regeneron Pharmaceuticals, Inc. or Ascendis Pharma A/S?
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Operational Costs Compared: SG&A Analysis of Regeneron Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Dr. Reddy's Laboratories Limited
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. and Vericel Corporation: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Evotec SE
SG&A Efficiency Analysis: Comparing Viatris Inc. and Ascendis Pharma A/S
Breaking Down SG&A Expenses: Walgreens Boots Alliance, Inc. vs Ascendis Pharma A/S
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Blueprint Medicines Corporation